SHIRLEY, NY, May 29, 2026 /24-7PressRelease/ — As emerging viral threats continue to challenge global healthcare systems, glycan-shielded viruses such as Ebola, Marburg, dengue, and Zika remain difficult targets for antibody discovery. Their dense glycan coatings help evade immune recognition, creating significant obstacles for vaccine research and therapeutic antibody development.
To support researchers working in this rapidly evolving field, Creative Biolabs is expanding its anti-glycan antibody development capabilities focused on viral glycan shield characterization and targeting.
Viral glycan shields are known to complicate epitope mapping, reduce antibody accessibility, and increase the difficulty of generating highly specific neutralizing antibodies. Researchers also face additional challenges, including:
• Complex glycosylation heterogeneity across viral strains
• Limited availability of high-quality glycan antigens
• Low immunogenicity of carbohydrate epitopes
• Difficulties in screening antibodies with strong glycan specificity
• Time-consuming validation workflows for antiviral candidates
According to scientists at Creative Biolabs, overcoming these barriers requires integrated glycoengineering expertise and advanced antibody screening technologies.
The company offers customized solutions for glycan-related antibody development targeting high-priority pathogens, including Ebola/Marburg glycan‑shield antibody development and flavivirus glycan‑shield antibody development. Its platform combines glycan synthesis, antigen design, hybridoma development, phage display, and high-throughput antibody characterization to accelerate discovery timelines.
“Glycan shields represent one of the most critical immune evasion mechanisms in virology,” said a scientist at Creative Biolabs. “Our goal is to help researchers identify glycan-targeting antibodies with improved specificity, sensitivity, and translational potential.”
Key service advantages include:
• Customized anti-glycan antibody generation strategies
• Expertise in viral glycoprotein and glycan shield analysis
• Multiple antibody screening and engineering platforms
• Flexible project design for academic and biopharma clients
• End-to-end support from antigen preparation to validation
“Creative Biolabs provided valuable scientific guidance throughout our glycan-targeting antibody project,” said one international virology research team. “Their expertise in glycan shield analysis and customized antibody screening significantly improved our workflow efficiency and helped accelerate early-stage candidate evaluation for complex viral glycoprotein studies.”
Creative Biolabs collaborates with research institutions, biotech companies, and laboratories across North America and Europe, providing globally accessible glycoimmunology and antibody engineering technologies to support worldwide researchers exploring innovative approaches against immune-evasive viruses.
Researchers seeking support for glycan‑shielded virus antibody discovery can learn more or request project consultation at https://www.creative-biolabs.com/anti-glycan-antibodies/.
About Creative Biolabs
Creative Biolabs specializes in anti‑glycan antibody discovery, viral glycan shield analysis, and glycoimmunology research support. With integrated capabilities spanning glycan synthesis, antigen design, and antibody engineering, the company partners with global researchers developing next‑generation antiviral therapeutics targeting immune‑evasive pathogens.
—
For the original version of this press release, please visit 24-7PressRelease.com here
Legal Disclaimer: The content on this page is syndicated from independent third-party providers. Kyrion Media makes no warranties or representations regarding the accuracy, completeness, legality, or reliability of the information, including text, images, videos, or licenses. If you are affiliated with this content or have any complaints, copyright concerns, or requests for removal, please contact us at retract@kyrionmedia.com with the specific URL of the content in question. We will review and address valid requests promptly.
